Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Raltegravir Pharmacokinetics and Safety in Neonates

Next Previous
Trial Profile

Raltegravir Pharmacokinetics and Safety in Neonates

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms IMPAACT-P1097

Most Recent Events

  • 02 Feb 2021 Data from 3 studies (TEmAA, IMPAACT P1026 & IMPAACT P1097) were used pharmacokinetic modeling framework to predict neonatal pharmacokinetics of transplacentally acquired emtricitabine, dolutegravir, and raltegravir, published in the Clinical Pharmacokinetics.
  • 09 Sep 2020 Results assessing safety and pharmacokinetics (raltegravir clearance) in low birth weight neonates born to pregnant women living with HIV and received raltegravir during pregnancy published in the JAIDS
  • 23 Jul 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top